These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2577 related items for PubMed ID: 17652294

  • 21. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [Abstract] [Full Text] [Related]

  • 22. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
    Maeda R, Minami Y, Haruki S, Kanbayashi K, Itani R, Suzuki A, Ejima K, Shiga T, Shoda M, Hagiwara N.
    Int J Cardiol; 2016 Jul 01; 214():419-22. PubMed ID: 27088403
    [Abstract] [Full Text] [Related]

  • 23. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.
    Vriesendorp PA, Schinkel AF, Van Cleemput J, Willems R, Jordaens LJ, Theuns DA, van Slegtenhorst MA, de Ravel TJ, ten Cate FJ, Michels M.
    Am Heart J; 2013 Sep 01; 166(3):496-502. PubMed ID: 24016499
    [Abstract] [Full Text] [Related]

  • 24. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873684
    [Abstract] [Full Text] [Related]

  • 25. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ.
    Eur Heart J; 2007 Nov 12; 28(21):2583-8. PubMed ID: 17483110
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P, Katsanos S, Joyce E, VAN DEN Brink OV, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA.
    J Cardiovasc Electrophysiol; 2015 May 12; 26(5):547-55. PubMed ID: 25648421
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator.
    Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, Valentino M, Brugada P.
    J Am Coll Cardiol; 1998 Apr 12; 31(5):1081-5. PubMed ID: 9562010
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H.
    Clin Res Cardiol; 2016 Nov 12; 105(11):953-961. PubMed ID: 27270758
    [Abstract] [Full Text] [Related]

  • 37. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P, Gadler F, Liv P, Mörner S.
    J Cardiovasc Electrophysiol; 2015 Oct 12; 26(10):1088-94. PubMed ID: 26178879
    [Abstract] [Full Text] [Related]

  • 38. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.
    Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, Gersh BJ, Ommen SR.
    Am J Cardiol; 2010 Nov 15; 106(10):1481-6. PubMed ID: 21059440
    [Abstract] [Full Text] [Related]

  • 39. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy.
    O'Mahony C, Lambiase PD, Rahman SM, Cardona M, Calcagnino M, Quarta G, Tsovolas K, Al-Shaikh S, McKenna W, Elliott P.
    Europace; 2012 May 15; 14(5):724-33. PubMed ID: 22094454
    [Abstract] [Full Text] [Related]

  • 40. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.
    Woo A, Monakier D, Harris L, Hill A, Shah P, Wigle ED, Rakowski H, Rozenblyum E, Cameron DA.
    Heart; 2007 Sep 15; 93(9):1044-5. PubMed ID: 17699173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 129.